After more than two years of downturn, the initial public offerings (IPOs) of American biotech companies are also an important indicator of the industry's health, finally showing signs of recovery. In the first six weeks of 2024, a series of biotech IPOs were witnessed, with most single financing amounts reaching approximately $100 million or more. These IPOs, combined with the recovery and surge in trading of two flagship biotech stock funds, give industry observers reasons for optimism. "Some of the current trends are moving in the right direction, and if they continue, we can be confident that the worst is over," said Mike Perrone, Managing Director of Baird Investment Bank